CSA scores $20.5M in Series B

CSA Medical has secured $20.5 million in a Series B financing to support its currently marketed Spray Cryotherapy system. Intersouth Partners and First Analysis led the financing, with S.V. Life Sciences, Rose Park, Blue Heron Capital and other existing investors participating. The system is comprised of a device and specialty catheters that allow delivery of therapeutic doses of a cryogen to freeze and destroy unwanted tissue inside the body. CSA release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.